{
  "Figure": "nihms848554_page14_383.jpg",
  "Figure_title": "Figure 1. Pharmacokinetics of Entrectinib at Steady-State (Continuous Daily Dosing) Mean steady state (Day 28) patient plasma concentration profiles at escalating dose levels  were plotted over the dosing interval following once-daily continuous dosing. The target  IC50 and IC90 values are based on entrectinib-induced tumor growth inhibition in mouse  xenograft models of NTRK1-rearranged colorectal cancer. "
}